ClinicalTrials.gg
CompletedNCT03233802IATP2Updated Nov 17, 2022

Individualized Assessment and Treatment for Alcoholism II

An interventional study of Individualized Assess & Treatment (IATP) and Packaged Cognitive-Behavioral (PCBT) in Alcoholism, sponsored by UConn Health. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by UConn Health · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2016, registered Jul 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The object of this study is to develop a treatment for alcohol use disorders that is more effective than current CB treatments. Through a 2009 R-21 pilot project the investigators developed a cognitive-behavioral (CB) treatment that employed cellphone-based experience sampling (ES) to collect detailed patient data, in near real-time, and that used those data to direct treatment for each patient based on his/her pattern of drinking and specific coping actions during high-risk situations. ES data included momentary assessments of situations, thoughts and feelings antecedent to drinking episodes, and the use of coping skills. That initial study of the Individualized Assessment and Treatment Program (IATP) showed promise. The present study is intended to extend the earlier findings, to compare IATP to a more active control treatment, and to evaluate long-term outcomes.

Read the detailed description

An 2009 R-21 pilot project developed a cognitive-behavioral treatment for alcohol use disorders that employs cellphone-based experience sampling (ES) to collect detailed patient data in near real-time, and uses those data to direct treatment for each patient based on his/her specific patterns of drinking and specific coping actions during actual high-risk situations. ES data included situations, thoughts and feelings antecedent to drinking episodes, and any use of coping skills. The object was to create a CB treatment that was more relevant for each patient and more effective than current treatments. In the initial study the Individualized Assessment and Treatment Program (IATP) yielded better drinking rates at posttreatment, and more adaptive changes in coping, than a conventional manualized CBT program. Moreover, changes in drinking were partly mediated by pre-to-posttreatment changes in coping with high-risk situations. Questions unanswered included:

  1. Because the pilot study only collected data pre- and posttreatment, with no follow-ups, it is not clear whether use of coping skills reduced drinking, or whether reduced drinking led to more adaptive coping.
  2. It was not known which coping skills or other factors drive outcomes in the long-term.

To answer these and other questions the investigators proposed to enroll 207 patients in a full-scale trial of IATP with extended follow-ups to examine determinants of outcomes over time. IATP will be compared to a more conventional packaged CB treatment (PCBT), and to a Case Management Control condition (CaseM), in a dismantling design. In addition to coping, a number of other possible treatment mechanisms suggested by the literature will be examined, including motivation, self-efficacy, self-control, social support, alliance with the therapist, AA involvement, mindfulness, and utilization of other treatment services.

By specifically training coping skills for use in high-risk for drinking situations, the investigators will be able to assess how skills per se contribute to initiation and long-term maintenance of behavior change. The use of ES during treatment will allow a determination of what patients are actually doing, in close to real time, to initiate and maintain their own sobriety. The use of ES in the follow-up period will allow the investigators to determine whether coping skills that were active in initiation of reduced drinking continue to be active in the long-term, as well as the extent to which other mechanisms may come into play. In this way investigators can develop a clearer picture of the processes that affect outcomes of CBT, and will enable clinicians to focus more precisely on the most relevant mechanisms of change. Comparing IATP with PCBT will test effects of tailoring skills. The use of CaseM will control for the general effects of study participation (i.e., "common factors"), especially therapist support. The study builds on pilot data and on procedures that have already been developed but not fully tested. This would be the first study to evaluate effects of treatment on actual behaviors and cognitions in high-risk situations as they occur.

02

Conditions studied

  • Alcoholism

Browse trials for

Keywords

  • Alcohol Use Disorder
  • Treatment
  • Cognitive-Behavioral Treatment
  • Individualized Treatment
03

In context

Alcoholism

1,634 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's enrollment of 173 is above the median of 88 across 1,395 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

UConn Health is the lead sponsor of 187 studies on the registry; 18 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years old,
  • Meet DSM-V criteria for Alcohol Use Disorder moderate-severe
  • Willing to accept random assignment to any of the three conditions

Exclusion criteria

Exclusion Criteria:

  • Acute medical or psychiatric problems that require inpatient treatment (e.g., acute psychosis, or suicide/homicide risk)
  • Reading ability below the fifth grade level
  • Lack of reliable transportation to the treatment site, or excessive commuting distance.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    Individualized Assess & Treatment (IATP)

    Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.

    Behavioral: Individualized Assess & Treatment (IATP)

  • Active comparator
    Packaged Cognitive-Behavioral (PCBT)

    Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.

    Behavioral: Packaged Cognitive-Behavioral (PCBT)

  • Active comparator
    Case Management (CaseM)

    Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.

    Behavioral: Case Management (CaseM)

Interventions

  • BehavioralIndividualized Assess & Treatment (IATP)

    See previous description

  • BehavioralPackaged Cognitive-Behavioral (PCBT)

    See previous description

  • BehavioralCase Management (CaseM)

    See previous description

06

What researchers measure

Primary outcomes

  1. Proportion of days abstinent (PDA)

    Proportion of days abstinent in the 90 days prior to each follow-up point

    Time frame: Every 3 months from intake through 21 months

Secondary outcomes

  1. Proportion Heavy Drinking days (PDH)

    Proportion of days in which heavy drinking occurred in the 90 days prior to each follow-up point

    Time frame: Every 3 months from intake through 21 months

  2. Drinker Inventory of Consequences (DrInC) score

    Negative life consequences of drinking

    Time frame: Every 6 months from intake through 21 months

07

Study locations

1 site
  • UConn Health
    Farmington, Connecticut 06030, United States
08

References and documents

Publications

  • Litt MD, Tennen H, Kadden RM. Individualized Assessment and Treatment Program (IATP) for alcohol use disorder: Comparison with conventional cognitive-behavioral treatment and examination of coping skills as a mediator of treatment. J Consult Clin Psychol. 2024 Oct;92(10):711-726. doi: 10.1037/ccp0000907. Epub 2024 Oct 7. PubMed 39374130 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03233802
Lead sponsor
UConn Health
Responsible party
Mark Litt (Professor of Behavioral Sciences, UConn Health) — Principal investigator
First posted
Jul 31, 2017
Start date
Aug 1, 2016
Primary completion
Nov 1, 2022
Completion
Nov 1, 2022
Last update
Nov 17, 2022

Study contacts

Mark D Litt
principal investigator · UConn Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion